CD19 and neuromyelitis optica: As previously said, the treatment of neuromyelitis optica includes anti-CD20 (e.g. rituximab) and anti-CD19 (e.g. inebilizumab) drugs that suppress the anti-aquaporin-4 autoantibodies production by B-cells; anti-C5 drugs (eculizumab) that inhibits the complement system; and anti-IL-6 (satralizumab or tocilizumab) that mitigates this cytokine production.